Roche pays $300 million upfront under agreement with Adaptive Biotechnologies to develop personalised cellular therapies for cancer httpswww.firstwordpharma.comnode1615837Â $RHHBY
Roche pays $300 million upfront under agreement with Adaptive Biotechnologies to develop personalised cellular therapies for cancer https://www.firstwordpharma.com/node/1615837 $RHHBY
More From BioPortfolio on "Roche pays $300 million upfront under agreement with Adaptive Biotechnologies to develop personalised cellular therapies for cancer https://www.firstwordpharma.com/node/1615837 $RHHBY"